XML 49 R39.htm IDEA: XBRL DOCUMENT v3.25.2
Strategic transactions and agreements - Ayala Pharmaceuticals - Narrative (Details) - Ayala Asset Purchase Agreement - USD ($)
$ / shares in Units, $ in Thousands
May 25, 2024
Mar. 25, 2024
Asset acquisitions    
Upfront consideration paid to Ayala $ 20,000 $ 20,039
Number of shares issued   2,175,489
Common stock issued   $ 50,645
Share price per share   $ 24
Percentage of discount related to unregistered share restrictions to be deducted from the share price   3.00%
Consideration paid   $ 71,341
Transaction costs   657
Maximum    
Asset acquisitions    
Payment to be made in cash   $ 37,500